Gain Therapeutics (GANX) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about GANX filings

Are insiders buying or selling Gain Therapeutics Inc (GANX) stock?

Neither. Gain Therapeutics Inc (GANX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GANX recently?

None. No member of Congress disclosed a GANX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GANX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

9 funds hold a position.

Questions about GANX filings

Are insiders buying or selling Gain Therapeutics Inc (GANX) stock?

Neither. Gain Therapeutics Inc (GANX) insiders filed no open-market purchases or sales in the 90 days to Nov 14, 2026, according to SEC Form 4 filings.

Which members of Congress have traded GANX recently?

None. No member of Congress disclosed a GANX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this GANX smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 10, 2026

Earnings came in 45.1% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 10, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.07+45.10% beat

-$0.13 expected

Revenue

$0.00

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

What the street expects next

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 10, 2026	-$0.07est. -$0.13	+45.10%beat	$0.00Yahoo Finance	No year-ago quarter
Jun 30, 2026Reported Aug 11, 2026	-$0.11est. -$0.14	+21.43%beat	Not on file	Not on file
Mar 31, 2026Reported May 11, 2026	-$0.13est. -$0.14	+4.88%beat	$0.00Yahoo Finance	No year-ago quarter
Dec 31, 2025Reported Mar 26, 2026	-$0.11est. -$0.14	+24.14%beat	$0.00Yahoo Finance	No year-ago quarter
Sep 30, 2025Reported Nov 12, 2025	-$0.15est. -$0.15	+2.17%beat	Not on file	Not on file
Jun 30, 2025Reported Aug 12, 2025	-$0.19est. -$0.17	-11.76%miss	Not on file	Not on file
Mar 31, 2025Reported May 14, 2025	-$0.16est. -$0.17	+5.88%beat	Not on file	Not on file
Dec 31, 2024Reported Mar 27, 2025	-$0.08est. -$0.19	+57.33%beat	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $1.12
High: $1.16
Low: $1.07
Prev close: $1.08
52-wk high: $4.34
52-wk low: $0.94
Mkt cap: $48.4M
ROE: -268.3%
Beta: 0.30
P/S: 255.5x
P/B: 4.2x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $48M

Valuation

P/S255.50
P/B4.17

Quality

Operating margin0.0%
ROE-268.3%
ROA-95.5%

Growth

Beta0.30

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

36balanced

20D volatility

85%annualized

52-week range

$1.11

$0.94$4.34

20D support

$0.94recent floor

20D resistance

$1.41recent ceiling

Returns

5D +0.0%20D -15.9%60D -45.3%

Price vs moving averages

SMA20 -4.6%SMA50 -25.8%SMA200 -39.2%

Volume pace

1.08xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 10, 2026

-$0.07est. -$0.13

+45.10%

$0.00Yahoo Finance

No year-ago quarter

Jun 30, 2026Aug 11, 2026

-$0.11est. -$0.14

+21.43%

Not on file

Mar 31, 2026May 11, 2026

-$0.13est. -$0.14

+4.88%

$0.00Yahoo Finance

No year-ago quarter

Dec 31, 2025Mar 26, 2026

-$0.11est. -$0.14

+24.14%

$0.00Yahoo Finance

No year-ago quarter

Sep 30, 2025Nov 12, 2025

-$0.15est. -$0.15

+2.17%

Not on file

Jun 30, 2025Aug 12, 2025

-$0.19est. -$0.17

-11.76%

Not on file

Mar 31, 2025May 14, 2025

-$0.16est. -$0.17

+5.88%

Not on file

Dec 31, 2024Mar 27, 2025

-$0.08est. -$0.19

+57.33%

Not on file

Gain Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about GANX filings

Questions about GANX filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 45.1% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Gain Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about GANX filings

Questions about GANX filings

How top traders are positioned

Unlock everything for $29/month

Earnings came in 45.1% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Gain Therapeutics Inc

Overview

Questions about GANX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Gain Therapeutics Inc

Overview

Questions about GANX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.